ImmuPharma PLC
  • Announcements
  • About Us
    • About Us
    • Our Team
    • Board of Directors
  • Our Science
    • Our Science
    • ImmuPharma Biotech
    • Key Clinical Investigators
  • Pipeline
    • Pipeline
    • Autoimmunity & Inflammation
    • Anti-Infectives
  • Partnerships & Collaborations
  • Investors
    • Investors
    • AIM Rule 26 Information
    • Regulatory News
    • Corporate Governance
    • Board of Directors
    • Annual Reports
    • Analyst Research
    • Interviews
    • Professional advisers
    • Email Alerts
  • Contact
Archives
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
September 30, 2015

Interim Results Announcement for the six months ended 30 June 2015

Read More
July 29, 2015

Richard Warr

Read More
July 27, 2015

ClinicalTrials.Gov registration of LUPUZOR™ Pivotal Phase III Trial

Read More
July 25, 2015

Term Sheet signed with US Investor to secure up to US$14 Million Funding For LUPUZOR™

Read More
June 25, 2015

Lupuzor’s Founder, Dr Slyviane Muller – Awarded Medal of Innovation from CNRS for Lupuzor™

Read More
May 29, 2015

ANNUAL GENERAL MEETING: 2015

Read More
May 07, 2015

Notice of Annual General Meeting: 29 May 2015

Read More
April 30, 2015

Preliminary Results Announcement for the year ended 31 December 2014

Read More
April 30, 2015

Dr Stéphane Méry Appointed as Non-Executive Director

Read More
February 11, 2015

Cancer Update: IPP-204106

Read More
January 27, 2015

Advance Assurance Received from H M Revenue and Customs Regarding “Enterprise Investment Scheme” Status

Read More
January 22, 2015

Landmark Collaboration Agreement & Commencement of Pivotal Phase III Lupuzor™ Study with Simbec-Orion

Read More
  • 1
  • …
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • Keep up-to-date with email alerts

  • @immupharma

Aim Rule 26 Contact informationDisclaimerPrivacy PolicySite map

© ImmuPharma PLC 2005-2022 | All rights reserved